Marco A. Calzado, Susanne Bacher and M. Lienhard Schmitz Pages 367 - 376 ( 10 )
The NF-κB/Rel signaling system is a paradigm for gene activation in response to inflammatory and menacing stimuli. Given the growing body of evidence showing an important involvement of NF-κB for the onset of autoimmune diseases and different types of cancer, NF-κB is an important drug target for the adjuvant therapy of these diseases. Great efforts have been made for the development of highly specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials. Here we discuss recent progress in the identification of druggable components of the NF- κB signaling system and the development and potential use of novel NF-κB inhibitors.
Inflammation,cancer,NF-κB,Inhibitor,IκB,IKK,Transcription factor
, , Institute of Biochemistry, Medical Faculty, Friedrichstrasse 24, Justus-Liebig-University, D-35392 Giessen Germany.